Improvement of TB endemia control – a witness of DOTS efficiency Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Statin use and the risk of tuberculosis: Data from 305,142 patients Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016
Liver injury in treatment of latent tuberculosis infection - is the age cut-off for treatment justified? Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Is it necessary to give tuberculosis treatment daily throughout? Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
Impact of drug injection using on TB-AIDS treatment outcomes Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013
Effect of anti-tuberculosis treatment on body composition during the intensive phase Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Hemoptysis: Causes, interventions and outcomes – Indian single centre experience Source: Annual Congress 2012 - New insights in the clinical management of lung diseases Year: 2012
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Increasing adherence to TB treatment – Pilot intervention in two counties in Romania Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011
Evaluation of hospital causes of death in patients with Tb in ten years Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013
Is there a need for prolonged follow up in mono-drug resistant TB? Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
Interim report: The effectiveness of smoking cessation in tuberculosis patients and its effective factor Source: International Congress 2016 – Smoking cessation strategies Year: 2016
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015
Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Tuberculosis costs in Spain and related factors Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016